Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30219110 | 0.90 | FDPS (0.52) | FDPSLMNAGGPS1GPR84 | |
| SCHEMBL6934259 | 0.90 | FDPS (0.52) | FDPSLMNAGGPS1GPR84 | |
| SCHEMBL5940515 | 0.90 | FDPS (0.52) | FDPSLMNAGGPS1GPR84 | |
| Ammonia Solution, Strong SCHEMBL20450627 | 0.88 | FDPS (0.39) | FDPSLMNASMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL28791834 | 0.84 | FDPS (0.43) | FDPSLMNASMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL9777464 | 0.82 | LMNA (0.62) | FDPSLMNAALDH1A1GGPS1TP53 | |
| Phosphine SCHEMBL23412618 | 0.82 | FDPS (0.53) | FDPSLMNAGPR84 | |
| Ammonia Solution, Strong SCHEMBL9710916 | 0.82 | FDPS (0.53) | FDPSLMNAGPR84 | |
| SCHEMBL28791875 | 0.82 | ALDH1A1 (0.40) | FDPSLMNASMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL4486788 | 0.81 | FDPS (0.45) | FDPSALDH1A1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | FDPS 4407/4885LMNA 4585/4885SMN1; SMN2 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.